Action on Climate Change Should Not Include Creation of New Entitlements
Over the last two years, the United States has scaled back Obama-era climate change policies, withdrawing from the Paris Agreement and rolling back climate-related regulations.
Carbon Tax Most Efficient in Tackling Climate Change
It is encouraging to see more and more fellow Republicans shed the reflexive skepticism about climate change that has characterized the GOP for years. Now, Republicans need to offer solutions.
Navigating the Evolving Opioid Crisis: A Conversation with House Committee on Energy and Commerce Republican Leader Greg Walden (R-OR)
On February 27, a panel of addiction experts and community leaders joined Rep. Greg Walden (R-OR) to discuss the nation’s ongoing efforts to curb opioid misuse and addiction.
Green New Deal Will Stifle Green Energy Innovation, Expert Says
The Washington Free Beacon referenced Alex Brill’s recent op-ed talking about the costs of the proposed Green New Deal.
“AEI resident fellow Alex Brill explained last week that regardless of cost, the unintended consequences of the Green New Deal are “the worst imaginable.”
MGA’a Alex Brill on KSRO
Brill discusses the opioid tax on big pharma in an interview for KSRO stating, “it’s going to result in higher prices for those opioids. But the out-of-pockets costs for the person filling the prescription is likely to remain the same.”
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
